Hutchison China MediTech Ltd

Hutchison China MediTech Ltd

Health CarePharmaceuticals & Biotechnology
  • Price (GBX)2,205.00
  • Today's Change-12.50 / -0.56%
  • Shares traded958.00
  • 1 Year change-12.06%
  • Beta1.2969
Data delayed at least 20 minutes, as of Jan 23 2017 10:49 GMT.
More ▼

Key statistics

On Monday, Hutchison China MediTech Ltd (HCM:LSE) closed at 2,205.00, -12.85% below its 52-week high of 2,530.00, set on Feb 04, 2016.
52-week range
1,612.50Apr 28 20162,530.00Feb 04 2016
Markit short selling activity
Previous close2,217.50
Average volume3.91k
Shares outstanding60.71m
Free float18.90m
P/E (TTM)--
Market cap1.34bn GBP
EPS (TTM)-0.5296 GBP
Data delayed at least 20 minutes, as of Jan 23 2017 10:49 GMT.
More ▼

Investors Chronicle View

The last IC recommendation on Hutchison China MediTech Ltd shares was Buy at 2,277.00 on 08 Dec 2016Read the full article

Board of Directors


Mr. Simon To, Executive Director and Chairman, Chi-Med


Mr. Christian Hogg, Executive Director and Chief Executive Officer, Chi-Med


Mr. Johnny Cheng, Executive Director and Chief Financial Officer


Mr. Shigeru Endo, Non-executive Director


Mr. Christian Salbaing, Non-executive Director


Ms. Edith Shih, Non-executive Director and Company Secretary


Mr. Michael Howell, Independent Non-executive Director


Professor Christopher Huang, Independent Non-executive Director


Mr. Christopher Nash, Senior Independent Director and Independent Non-executive Director

2013 Full year results

Investor Relations Contact

Mr. Christian Hogg  
Chief Executive Officer
Address: 21st Floor, Hutchison House,
10 Harcourt Road, Hong Kong

Tel:  +852 2121 8200
Fax:  +852 2121 8281
Email:  ir@chi-med.com

© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.